Investments & digital assets › F8949.A.X238
F8949.A.X238 · federal · F8949 line A.X238
Delmar Pharma (acquired 2024-09-24, sold 2025-01-21; proceeds 1,335.98, basis 1,432.50)
-96.52
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 3 · field X238_desc · “Lot X238 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 3 · field X238_acq · “Lot X238 date acquired”
read as “09/24/2024” → 2024-09-24
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 3 · field X238_sold · “Lot X238 date sold”
read as “01/21/2025” → 2025-01-21
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 3 · field X238_proceeds · “Lot X238 proceeds”
read as “1,335.98” → 1,335.98
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 3 · field X238_basis · “Lot X238 cost basis”
read as “1,432.50” → 1,432.50
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 3 · field X238_wash · “Lot X238 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: -96.52v2 · 2026-03-19: -96.52v3 · 2026-06-23: -96.52
Adjust this number
Evidence & discussion
Record how you verified it